Thursday, February 9, 2017

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=1010672

Feb 7, 2017
- GW intends to advance oncology research and development efforts -
LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme, or GBM. GBM is a particularly aggressive brain tumor, with a poor prognosis. GW has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for THC:CBD in the treatment of glioma.
The study showed that patients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort (p=0.042). Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group. THC:CBD was generally well tolerated with treatment emergent adverse events leading to discontinuation in two patients in each group. The most common adverse events (three patients or more and greater than placebo) were vomiting (75%), dizziness (67%), nausea (58%), headache (33%), and constipation (33%). The results of some biomarker analyses are still awaited.
"The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo and this is a good signal of potential efficacy," said Professor Susan Short, PhD, Professor of Clinical Oncology and Neuro-Oncology at Leeds Institute of Cancer and Pathology at St James's University Hospital and principal investigator of the study. "Moreover, the cannabinoid medicine was generally well tolerated. These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment."
"We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma," stated Justin Gover, GW's Chief Executive Officer. "These data are a catalyst for the acceleration of GW's oncology research interests and over the coming months, we expect to consult with external experts and regulatory agencies on a pivotal clinical development program for THC:CBD in GBM and to expand our research interests in other forms of cancer."
The study, designed to evaluate a number of safety and efficacy endpoints, comprised an initial phase where the safety of THC:CBD in combination with dose-intense temozolomide (an oral alkylating agent that is a standard first-line treatment for GBM) was assessed in 2 cohorts of 3 patients each.  Following a satisfactory independent safety evaluation, the study then entered a randomized placebo-controlled phase where 12 patients were randomized to THC:CBD as add-on therapy compared with 9 patients randomized to placebo (plus standard of care). 
Beginning in 2007 and prior to initiating this study, GW conducted substantial pre-clinical oncologic research on several cannabinoids in various forms of cancer including brain, lung, breast, pancreatic, melanoma, ovarian, gastric, renal, prostate and bladder. These studies have resulted in approximately 15 publications and show the multi-modal effects of cannabinoids on a number of the key pathways associated with tumor growth and progression. Cannabinoids have been shown to promote autophagy (the process of regulated self-degradation by cells) via several distinct mechanisms, including acting on the AKT/mTOR pathway, an important intracellular signalling pathway that is overactive in many cancers.
In glioma, THC and CBD appear to act via distinct signalling pathways. The combination of THC and CBD showed good efficacy in various animal models of glioma, particularly when used in combination with temozolomide. Initial in vitro studies showed that the combined administration of THC and CBD led to a synergistic reduction in the viability of U87MG glioma cells when compared to the administration of each cannabinoid individually. The co-administration of temozolomide with THC and CBD had further synergistic effects, causing a significant reduction in cell viability. These pre-clinical studies justified the initiation of the Phase 2 clinical study.
GW's portfolio of intellectual property related to the use of cannabinoids in oncology includes a number of issued patents and pending applications in both the U.S. and Europe. This portfolio is designed to protect the use of various cannabinoids individually or in combination, in the treatment of a variety of oncology-specific disorders and product formulations.
About GBM
Gliomas are tumors that arise from glial cells mainly in the brain but can also be found within the spinal cord. Within the category of Glioma there are multiple different tumor types. GBM is the most common Glioma and is one of the most common primary brain tumors, accounting for 15.6% of all primary brain tumors (Ostrom et al. 2013). They are also the most aggressive with only 28.4% of patients surviving one year and only 3.4% surviving to year five (Brodbelt et al. 2015). Studies of patients with high-grade gliomas showed that headache was the most common initial presenting symptom. These headaches can be persistent lasting more than six months and are often associated with other symptoms, including seizures, visual disturbances, cognitive impairment and nausea and vomiting depending on the location and growth rate of the tumor.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Forward-looking statements
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Sativex® and Epidiolex® and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Monday, December 26, 2016

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.

https://www.ncbi.nlm.nih.gov/pubmed/27778331

Friday, December 16, 2016

U.S.: Hemp Industry Association Says DEA Ruling Does Not Make CBD Illegal

http://crrh.org/news/blog/1582

By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
- See more at: http://crrh.org/news/blog/1582#sthash.8DMXosgI.dpuf

By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
- See more at: http://crrh.org/news/blog/1582#sthash.8DMXosgI.dpuf
 
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
 
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
 
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
hemp field.jpg
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
hemp field.jpg
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf
hemp field.jpg
By Derrick Stanley
Hemp News
The National Hemp Association has made an announcement that a recent ruling by the U.S. DEA (Drug Enforcement Administration) did not make cannabidoids (CBD) illegal.
The following statement was issued by the Hemp Industries Association:
Yesterday the Drug Enforcement Administration (DEA) issued a Final Rule on the coding of marijuana extracts. Unfortunately some misleading media stories and social media postings lead quite a few people to panic at reports that CBD was being banned under this new rule.
The Sky is NOT Falling. The Final Rule published by DEA did not change the legal status of CBD. This can only be done by a scheduling action which has NOT occurred.
HIA has carefully reviewed this with our legal advisors and discussed it with industry experts. While there are some differing opinions on the effect of the rule, there is general agreement that yesterday's ruling did not change the status of CBD. Here are some important facts to know:
Cannabidiol is not listed on the federal schedule of controlled substances
Sec. 7606 of the Farm Bill defines hemp as distinct from marijuana and does not treat it as a controlled substance when grown under a compliant state program.
Despite these facts, DEA has stated that CBD is a controlled substance previously.
HIA strongly disagrees with the DEA position and is ready to take action to defend should DEA take any action to block the production, processing or sale of hemp under Sec. 7606.
The Final Rule published on December 14th was not a scheduling action but rather an administrative action related to record keeping.
- See more at: http://crrh.org/news/DEA-did-not-make-CBD-illegal-after-all-despite-reports-to-the-contrary#sthash.hLXbgO4d.dpuf

Friday, November 25, 2016

Cannabinoids Improve Efficiency Of Mitochondria And Remove Damaged Brain Cells

http://www.collective-evolution.com/2013/05/30/new-study-shows-cannabinoids-improve-efficiency-of-mitochondria-and-remove-damaged-brain-cells/

mary j
  We're creating a positive news network. We need your help.
mjA recent study conducted by Andras Biokei-Gorzo at the Institute of Molecular Psychiatry at the University of Bonn in Germany is suggesting that marijuana(or the activation of the brain’s cannabinoid system) triggers the release of antioxidants, which act as a cleansing mechanism. This process is known to remove damaged cells and improve the efficiency of mitochondria. Mitochondria is the energy source that powers cells.  The study was published in Philosophical Transactions Of The Royal Society, B. You can read the entire study here.
These discoveries shed new insight on how natural marijuana cannabinoids hold the capacity to literally kill the brain inflammation responsible for causing cognitive decline, neural failure, and brain degeneration. By supplying these receptor sites with cannabinoids, patients may be able to overcome brain conditions like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and more, not to mention premature brain aging. The human brain contains an extensive network of special receptor sites that modulate nervous system function only when activated by the appropriate cannabinoid compounds, which are found in the marijuana plant.
Cannabinoids refer to any of a group of related compounds that include cannabinol and the active constituents of cannabis. They activate canbinoid receptors in the body. The body itself produces  compounds called endocannabinoids and they play a role in many processes within the body that help to create a healthy environment. Cannabinoids also play a role in immune system generation and re-generation. The body regenerates best when it’s saturated with Phyto-Cannabinoids. Cannabinoids can also be found in Cannabis. Cannabinoids may very well be the best cancer fighting substance out there!
Cannabinoid system activity is neuroprotective, and increasing it could be a promising strategy for slowing down the progression of brain aging and for alleviating the systems of neurodegenerative disorders -Andras Biokei
Gery Wenk, a professor of neuroscience, immunology and medical genetics at Ohio State University conducted some of the research that came out of the study from Germany. He stated that this is a positive step, and that it is encouraging to see the potential development of cannabinoid solutions without going overboard. Here is what he said.
I’ve been trying to find a drug that will reduce brain inflammation and restore cognitive function in rats for over 25 years; cannabinoids are the first and only class of drugs that have ever been effective. I think that the perception about this drug is changing and in the future people will be less fearful. – Gerry Wenk, Professor of neuroscience, immunology and medical genetics at Ohio State University
Biokei-Gorzo and his collegues said that the greatest hurdle for moving forward with their research are the social and political challenges. This isn’t something new, our world seems to be dominated by belief systems instead of obvious fact. It’s discouraging to see beliefs  and persuasion overrule truth. At the same time it’s very encouraging to see truth slowly creep its way into the norm. That’s always how it has been done throughout human history. It’s quite evident that the powers that be do not want to legalize marijuana, and we know that they do not have our best interest at hand. If it was legalized, I’m sure it would be distributed and tweaked by big pharmaceutical companies.
On the other hand there have been a number of studies that show how marijuana can actually reduce brain power and impair working memory. The amount of studies that show the potential benefits of marijuana is outstanding, and the potential harmful effects are in the few, if any at all. As far as medicinal use goes, I think that is a no brainer. I definitely believe nature intended marijuana to be used for its health and healing properties.
Sources:
http://cannabisinternational.org/
http://edrv.endojournals.org/content/27/1/73.fullhttp://cannabisclinicians.org/wp-content/uploads/2011/12/OS-2011-Terpenes+Minor-CBs.pdf

Friday, September 23, 2016

U.S. Attorney General Admits Marijuana Is Not a Gateway Drug

https://www.merryjane.com/news/us-attorney-general-admits-marijuana-not-gateway-drug

Top federal official crushes this popular anti-legalization argument.

One of the most popular arguments against the legalization of marijuana is that pot is a “gateway” drug with the potential to turn the great American populous into a nation of dope fiends. But today the country’s leading law enforcement official denounced this common misconception by admitting that the consumption of marijuana does not lead to the use of harder drugs.
As part of what President Obama has declared National Prescription Opioid and Heroin Epidemic Awareness Week, U.S Attorney General Loretta Lynch appeared at town hall meeting this morning in Richmond, Kentucky to discuss the dangers of opioid abuse with a group of teens.
In her opening statement, Lynch was adamant that the leading culprit behind Kentucky’s heroin epidemic was the use of prescription drugs.
“When you look at someone that, for example, has a heroin problem, it very often started with a prescription drug problem. Something totally legal. Something in every medicine cabinet. Something you can have prescribed to you in good faith by a doctor,” Lynch said before taking questions from the audience.
It did not take long before the discussion turned to the issue of marijuana.
Tyler Crafton, a student at Madison Central High School, took the opportunity to ask Lynch whether she thought the recreational use of marijuana among high school kids would lead to opioid abuse.
Shockingly, Lynch, the top dog at the U.S. Department of Justice, did provide the young man with a response straight out of the federal government’s propaganda handbook.
“There a lot of discussion about marijuana these days. Some states are making it legal, people are looking into medical uses for it, and I understand that it still is as common as almost anything,” Lynch replied. “When we talk about heroin addiction, we unusually, as we have mentioned, are talking about individuals that started out with a prescription drug problem, and then because they need more and more, they turn to heroin. It isn’t so much that marijuana is the step right before using prescription drugs or opioids.”
For a moment, it sounded as though the Attorney General was preparing to backtrack on her statement to some degree, adding that, “if you tend to experiment with a lot of things if life you may be more inclined to experiment with drugs.”
But then Lynch followed up with what should be considered one of the most important statements a federal official has made in 2016.
“It’s not as though we are seeing that marijuana is a specific gateway,” she said.
The attorney general’s admission that marijuana is not a gateway drug is fairly consistent with the National Institute on Drug Abuse, which finds “the majority of people who use marijuana do not go on to use other, “harder” substances. Yet many of marijuana’s opposing forces are going up against ballot measure in several states this election season by trying to convince the general public that legal weed will cause the opioid epidemic to spin further out of control.
Interestingly, an investigational report published earlier this week by the Associated Press and the Center for Public Integrity found that lobbyists for the drug makers responsible for the same prescription drugs that Attorney General Lynch says is responsible for the opioid epidemic have spent $880 million legally bribing state representatives and senators to vote against legislation concerning the restricting of opioid use. It stands to reason that these lobbyists are also responsible for getting federal lawmakers to turn a blind eye to marijuana.
Attorney General Lynch will be speaking at more than 250 events this week in support of Prescription Opioid and Heroin Epidemic Awareness Week. It will be interesting to see if she offers additional comments about the safety of marijuana.

Tuesday, September 20, 2016

Where to find good quality RSO or Hemp Extracts?

I get this question quite a bit, if you aren't able to make the oil yourself, then here is a list of legit providers

California
California Tears
Synergy Wellness

Oregon
Genesis Pharms

Washington
Health Max Group  (CBD Only)

Worldwide
Hemp Oil Shop
Endoca (CBD Only)

Monday, September 5, 2016

Boy on His Deathbed is Cured with Cannabis

1455762186682
In a last ditch effort to save his life, 17-year-old Alexander “AJ” Kephart’s dedicated parents, Sheila and Chris, decided to try out cannabis oil on their dying son with miraculous results. Here’s one American family’s painful, inspirational, devastating and heroic medical cannabis cures-cancer story.
AJ’s super supportive father, Chris, admits his son’s story is complicated–even doctors have a hard time understanding everything he is now “missing” and how he’s been put back together (with titanium, prosthetics and even a “cage” around his back after having three vertebrae removed).
It all started in August 2012 when AJ noticed a persistent pain in his knee. In January 2013, he was diagnosed as having bone cancer. Later it was found that he also had stage four lung carcinoma as well.
That’s when AJ started chemotherapy. In May of the same year, his entire knee was removed along with some bone in his thigh and calf. At this point, doctors also found six tumors on all four of his lung chambers. To keep his lungs from collapsing, AJ was kept in the hospital for months hooked up to a breathing apparatus.
AJ was healing up when the cancer returned in 2014. He had his first three vertebrae removed, his top two ribs and sections of his back removed. The surgery itself even had to be stopped halfway as AJ was losing the use of his nerves. He ended up having to wear a cage around his body until the surgery could be completed a week or so later.
Just a few months after the spine surgery, AJ’s oncologist, Dr. Susan Storch, informed Sheila and Chris that his left lung lobe was covered with 20 plus cancerous tumors. They started chemo. Again.
Aj
That’s when they got the news: It’s time to “get your son’s things in order,” said the doctors. They gave AJ only a month more to live.
In complete desperation, Sheila and Chris asked their doctor about medical cannabis and its cancer-fighting effects. Dr. Storch agreed cannabis oil would be a good “alternative” medicine to pursue along with another series of chemotherapy sessions. She recommended cannabis pioneer Dr. Bonni Goldstein.
In her Lawndale, California office, Dr. Goldstein explained how cannabinoids–especially CBD–work by telling cancer cells to commit suicide plus it stops the formation of new capillaries, which cancer cells need to grow and spread. But even Dr. Goldstein had to admit AJ’s case was going to be experimental as she has never before treated a child with this particular cancer.
On the way home to Simi Valley, the Kepharts made a stop in Beverly Hills to Tracy Ryan’s then new cannabis clinical built specifically for children, CannaKids. “When we met AJ, he was super frail and was wearing a neck brace. He was taking handfuls of pain medications daily. His Mother Sheila was terrified and she looked like her soul had been ripped out,” remembers Ryan, whose daughter Sophie was healed of a brain tumor via cannabis oil.
In fact, AJ was in excruciating pain. His father Chris says AJ was taking two of the following each day for pain: OxyContin, Norco, Tylenol and Motrin. Without the pain killers, AJ would scream and cry in horrendous pain whenever he was awake.
After five days on CBD and THC oils by CannaKids, Chris says AJ’s pain has decreased so much that he was down to taking only one OxyContin daily. “Wow,” he exclaimed when remembering this stress-relieving moment for the whole family.
Because AJ had nothing to lose, his loving parents decided to speed up the dosage process. Dr. Goldstein had recommended a three-month process to increase the dosage, but Chris decided to fly at warp speed.
In two weeks, AJ was up to the highest dosage, but he was also tired all the time and felt loopy. “No, son,” father Chris said to AJ, “you are just stoned out of your mind.” Chris admits that this was a sad, but comical moment for father and son.
Two months later, the Kepharts visited their oncologist who was shocked that AJ looked much better and stronger. She also discovered his white blood cell counts showed lots of improvement. Four months later, a scan showed the multiple tumors on AJ’s lungs were completely gone.
Chris says Dr. Storch told them something like: “I can’t explain it. There’s no reason for it. But your scan came back totally clear. There’s no cancer. There’s no tumors in his lungs. It’s all gone.”
Since then, every scan has shown there’s no longer any cancer. “I believe cannabis is keeping him alive,” says Chris.
Very unfortunately, high dosage medical grade cannabis oil is expensive and costs the Kepharts almost $2,000 a month to keep AJ cancer and pain free. The stress this financial burden has put on the family has even affected AJ’s mental health.
“He was freaking out about everything,” says Chris, who made sure to provide AJ with a psychotherapist and as relaxing an environment as he can provide given the extreme circumstances.
Today, AJ is still cancer free. He has completely stopped chemotherapy after having more complications. He and his family are seeking less expensive ways to get high-grade cannabis oils, but they have yet to find a more affordable answer before this health crisis literally puts the family in bankruptcy.
AJ’s very brave cancer survival story truly is a medical miracle and another reason cannabis needs to be legalized and affordable for everyone who needs it.
www.gofundme.com/ajkephart

http://ireadculture.com/boy-on-his-deathbed-is-cured-with-cannabis/

normally we do not post testimonials, but this one was especially touching